Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03898180 |
|---|---|
| Brief Title: | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) |
| First Submitted : | March 29, 2019 |
| First Submitted that Met QC Criteria : | March 29, 2019 |
| First Posted : | April 1, 2019 |
| Results First Submitted : | October 6, 2023 |
| Results First Submitted that Met QC Criteria : | October 6, 2023 |
| Results First Posted : | October 31, 2023 |
| Last Update Submitted that Met QC Criteria : | January 11, 2024 |
| Last Update Posted : | February 6, 2024 |